All In Biotech

Drug Trial Radar · NCT07937501

A Study of IPG11406 Tablets in Participants With Lupus Nephritis

A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety, Efficacy, And Pharmacokinetics Of IPG11406 Tablets In Participants With Lupus Nephritis

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Nov 20, 2026

Primary completion

Nov 20, 2028

Study completion Nov 20, 2029

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Lupus Nephritis (LN) is one of the most serious and common complications of Systemic Lupus Erythematosus (SLE). It is a chronic inflammatory disease triggered by abnormal autoimmunity and the deposition of immune complexes in the kidneys. Approximately 40% to 60% of SLE patients develop lupus nephritis at the onset of the disease, and the cumulative rate of kidney involvement during the course of the disease can even reach 90%. The goal of this Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety, Efficacy, And Pharmacokinetics Of IPG11406 Tablets In Participants With Lupus Nephritis trial is to evaluate the efficacy ,safety and tolerability of different doses of IPG11406 tablets combined with standard treatment compared to placebo combined with standard treatment in participants with active lupus nephritis. A total of 4 groups were designed the 10mg IPG11406 tablet group, the 20mg IPG11406 tablet group, the 40mg IPG11406 tablet group,and the placebo group. The ratio among the groups was 1:1:1:1. Participants were randomly assigned to the above 4 dosage groups, with 48 participants planned for each group, totaling approximately 192 participants enrolled. After randomization, participants will receive a 24-week double-blind treatment, twice daily (BID).They will take the assigned study drug (IPG11406 tablets at 40mg, 20mg, 10mg or placebo) orally.Throughout the 24-week core treatment period, all participants in all groups should continue to receive the standard treatment as prescribed by the protocol. The primary efficacy endpoint of the renal response will be determined by changes in proteinuria and renal function. For the renal function assessment in the study visits, the glomerular filtration rate will be estimated using the CKD-EPI formula; proteinuria will be evaluated using the urine protein-to-creatinine ratio (based on the 24-hour urine collected).

Conditions

  • Lupus Nephritis

Interventions

  • IPG11406 tabletDrug

    Twice daily, oral administration for 24 weeks.

  • placeboDrug

    Twice daily, oral administration for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of participants who achieved complete renal remission (Completerenalresponse, CRR) at the 24th week.Time frame: From enrollment to the end of treatment at 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing DrumTower Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.